benefit of two of the newer drugs for osteoporosis

November 1998

There's good news about the benefit of two of the newer drugs for osteoporosis...Evista (raloxifene) and Fosamax (alendronate).

Evista is a selective estrogen receptor modulator (SERM). Lilly markets it now in the U.S...soon in Canada.

Evista has now been shown to prevent FRACTURES...initially it was shown just to increase bone density.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

STANDARDIZED herbal products
Diabetes confused about the readings they're getting from the newer blood glucose meters
Interactions significant interaction when verapamil is combined with lovastatin (Mevacor) or simvastatin (Zocor)
Cardiology new antiplatelet drug called Plavix
Cardiology starting most heart failure patients on "triple therapy"
Cardiology now marketing Nitrolingual Pumpspray
Hypertension Atacand (candesartan), a new angiotensin II receptor blocker (ARB) for hypertension
gabapentin (Neurontin) for psychiatric disorders
Paxil (paroxetine) or other SSRIs for social phobia
SSRIs can increase the risk of falls in the elderly
Periostat, a new "pill" for periodontitis
Infectious Diseases lamivudine for chronic hepatitis B
Infectious Diseases This year's flu vaccine may be especially beneficial
Infectious Diseases two promising antivirals to treat and prevent influenza
cautioning about the use of albumin in seriously ill patients
Osteoporosis benefit of two of the newer drugs for osteoporosis
Osteoporosis pharmacists now offer bone density tests
folic acid supplements substantially reduce the risk of colon cancer